Home / Press Release / Global Opioid Induced Constipation (OIC) Drugs Market Expected To Reach US$ 3,770.4 Mn By 2026

Global Opioid Induced Constipation (OIC) Drugs Market Expected To Reach US$ 3,770.4 Mn By 2026

The latest market report published by Credence Research, Inc. “Opioid Induced Constipation (OIC) Drugs Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global opioid induced constipation drugs market was valued at US$ 2,430.6 Mn in 2017, and is expected to reach US$ 3,770.4 Mn by 2026 expanding at a CAGR of 4.92% from 2018 to 2026.

Browse the full report Opioid Induced Constipation (OIC) Drugs Market - Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market

Market Insights

In the present scenario, drugs such as osmotic laxatives and stimulant cathartics which are prescribed by physicians during the initial treatment of opioid induced constipation are leading the drug type segment. Naloxegol will register significant growth owing to its enhanced drug safety and tolerability in comparison to other mu-receptor antagonists prescribed for opioid induced constipation.

Prescription drugs are currently dominating the global market due to increasing number of patients not gaining relief from opioid induced constipation from over the counter laxatives and stimulant cathartics. Over the counter products show therapeutic effect only in patients taking opioid analgesics for 3-4 weeks.

Increasing number of patients suffering with non-cancer pain disorders such as rheumatoid arthritis and osteoarthritis are prescribed opioid analgesics which causes constipation will drive the OIC drugs market. Homecare settings are widely using drugs to treat opioid induced constipation for patients seeking palliative care. Asia Pacific will showcase rampant growth owing to huge population base suffering with chronic pain related to occupational hazards and poor regulations results in large adolescent population engaged in opioids misuse.

Manufacturers are constantly striving to provide drugs to treat OIC with least side effects. Recently naldemedine (Symproic) received USFDA approval for the treatment of chronic constipation induced by opioids in adults. Shionogi, Inc. the developer of the drug molecule has also registered a petition with the FDA for the removal of the controlled substance classification. Naldemedine will register excellent growth owing to enhanced drug safety and efficacy and probability to be sold as over the counter product. EA Pharma Co. Ltd has applied a JNDA for elobixibat in Japan for the treatment of chronic constipation; which will further drive the opioid induced constipation drugs market during the forecast period from 2018 to 2026.

The key players pioneering in the opioid induced constipation drugs market are AstraZeneca, Cubist Pharmaceuticals (Adolor Corporation), Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals, Inc., Pfizer, Inc., Progenics Pharmaceuticals, Inc., Salix Pharmaceuticals Ltd., Shionogo & Co Ltd., Sucampo Pharmaceuticals, Inc., and Synergy Pharmaceuticals, Inc.

Key Market Movements:

Contact Information
24/7 Research Support
Phone: +1-800-361-8290
sales@credenceresearch.com
Get in Touch with us
Join us on Facebook
Follow us on Twitter
Join us on LinkedIn
Add us on Google +